Fullerton Healthcare Redeems US$175m 7.0% Senior Perpetual Capital Securities, Underscoring Resilience Amidst COVID-19 Uncertainty

SINGAPORE, Apr 6, 2020 – (ACN Newswire) – Fullerton Healthcare Corporation Limited (“Fullerton Health”), the leading integrated healthcare platform in the Asia Pacific, announces that it has fully redeemed its US$175 million senior perpetual capital securities today, underscoring its financial resilience and commitment to stakeholders amidst economic uncertainty arising from the COVID-19 pandemic.

The redemption of the 7.0% senior perpetual capital securities (ISIN Code: XS1589875548) was made on the first call date (6 April 2020), funded by a combination of internal and external resources.

The proceeds from the perpetual securities had helped Fullerton Health expand geographically, add new capabilities and service offerings, and deepen core markets presence. With operations in nine markets, more than 6,500 staff, over 500 owned facilities and a network of over 12,000 third party providers, Fullerton Health is vertically integrated across a range of services, including managed care and network management, primary care, diagnostics, ancillary and speciality care.

“We would like to take this opportunity to thank the investors of the perpetual securities for their confidence, trust and strategic input over the last three years. Our ability to combine internal and external resources to redeem the perpetual securities underlines the trust placed in the operational and financial strength of Fullerton Health. We will continue to execute our mission to provide affordable and accessible care for all in the Asia Pacific,” said David Sin, Group President of Fullerton Health.

While the pandemic has affected all healthcare operators, Fullerton Health has been well prepared with its diversification strategy across markets and its service lines, built and well-executed over the years. It serves to buffer the impact of the COVID-19 situation.

“Our robust and quick infection control response ensures the safety of our staff and viability for patients to access quality care. Our close operational relations with key clients allow us to customise support efforts to help them care for their employees’ health and well-being during this difficult time,” said Ho Kuen Loon, Group Chief Executive Officer of Fullerton Health.

About Fullerton Health

Fullerton Health is a leading integrated health system in the Asia Pacific region. Founded in Singapore in 2010, today the Company serves clients through over 500 healthcare facilities and a large global network of healthcare providers across nine markets in the Asia Pacific. Fullerton Health’s value proposition is the integration of healthcare service offerings with customized management and advisory capabilities, in line with its purpose to deliver affordable and accessible care for all in the Asia Pacific. For more information on Fullerton Health, please visit http://www.fullertonhealth.com/.

For more information, please contact:
Isaac Tang
WeR1 Consultants
D: +65 6737 4844
M: +65 9178 0269
E: fullertonhealth@wer1.net

Contentos Announces Partnership with Theta Network

NEW YORK, NY, Apr 6, 2020 – (ACN Newswire) – Content public blockchain Contentos (COS) announced that they signed an agreement with Theta Network (THETA) to accelerate development of video optimization and user experience with Contentos and its video platform, COS.TV. Since its launch 10 months ago, COS.TV has had more than 1.5 million minutes of videos uploaded from creators around the world. More than 20,000 videos are uploaded every week, and users watch over 500,000 minutes of videos every day. Every user can earn platform incentives on COS.TV by watching videos, uploading videos, leaving comments, liking videos, voting for BP, and participating in community activities.

Theta Network, which has received investment from Samsung NEXT, gives users the opportunity to share bandwidth and other computing resources with their community via a decentralized peer-to-peer network. Users earn tokens as a reward for contributing to the mesh content delivery network. Contentos and Theta have a common goal to build the best decentralized video platform and the projects aim to improve creator and user experiences in the field of video creation and related areas.

About Contentos
Contentos (COS) is a decentralized global content ecosystem, which is invested jointly by Matrix Partners China, IDG, Gobi, and supported by Ontology, DHVC, Node Capital, Binance Lab, LD Capital, etc. Contentos aims to build the public chain platform that brings values back to content creators and users.

Contentos has reached a strategic partnership with the photo-editing tool PhotoGrid, the well-known live broadcast platform LiveMe, and the short-video platform Cheez. These three products have brought Contentos millions of global content creators and 60 million monthly users. In addition, Cheetah Mobile’s CleanMaster and related game products are also directly involved in the Contentos ecosystem.

About Theta Network
Theta Network (Theta) aims to develop a more efficient way to distribute any type of content and data worldwide through an incentivized peer-to-peer network. The Theta blockchain uses its tokens to encourage individual users to share excess computing power and bandwidth resources as a relay node for video streams. This mechanism can improve the quality of video streams and solve the “last mile” transmission problem, which is the main bottleneck of traditional information transmission channels, especially for 4K, 8K video and next-generation VR video. With sufficient network density, most users can pull video streams from peer Theta nodes, and video platforms can significantly reduce their costs of content delivery. Theta Network introduces a token reward mechanism to help video platforms to attract users, increase revenue, and provide a more engaging viewing.

Contentos
Ava Wen
ava@contentos.io
+886920686876

Azabu Insights: Survey Shows 34% increase in Mask Usage in Tokyo

TOKYO – (JCN Newswire) – A group of strategy consultants at Azabu Insights, Tokyo, Japan have been analyzing the coronavirus outbreak since its onset. We are continually looking for insights to share in the hope that they can help people or companies through this difficult time.

On March 13th an Azabu Insights survey showed that only sixty-four percent of commuters in central Tokyo were wearing masks. While no February survey was conducted, we believed that masks usage was significantly higher in February when the early cases of coronavirus were detected in Japan. Our researchers concluded that the reason mask usage was down was that supplies had run out, “masks have been sold out at the convenience stores for at least a week now and shipments from Amazon are expected to take ten days to two weeks.”

Another consideration could have been that the spring had come, young Tokyoites felt they had largely beaten the coronavirus and it was time to get out. At the time the Prime Minister was still optimistic the Olympics might happen this year. Whatever the reason, mask-usage was almost definitely lower than it had been a few weeks earlier.

As the coronavirus situation continues to evolve globally and has also received renewed focus in Japan, Azabu Insights refreshed this survey data on April 2nd. The data showed there has been a significant uptick in mask usage with eighty-six percent of people surveyed now wearing masks.

Drivers for Increase in Usage: Change in Tone from the Top?

While the drivers for the increase are not altogether clear there are a number of factors that we look to for guidance.

There has been a distinct change in tone from the top. Prime Minister Abe, Tokyo Mayor Koike as well as many politicians are now wearing masks during parliament and press conferences. The 2020 Olympics have been delayed, which may have freed the government to make more direct statements. They have conducted press conferences with the MHLW urging people to abstain from nightlife, such as bars and karaoke. The MHLW has noted that nightlife has been a source of infection clusters in Japan. Mayor Koike has raised the possibility of a lockdown of Tokyo.

Looking at supply, masks still seem perpetually sold out at the convenience stores and there is a continuing backlog on Amazon. That said, the government had made a commitment to increasing the supply. People seem to have gotten their hands on supply somehow and we also expect that many people have started re-using masks across multiple days. Note we do not believe the increase in usage is a result of utilizing hand-made masks, which continue to be less than five percent of masks observed.

The West is Catching the Mask Craze

Also during this period there has been a significant change in opinion in western countries with a large number of important figures recommending them, starting with an opinion piece by researchers at Yale on March 19th. Former Harvard School of Public Health dean, Harvey Fineberg also agreed, saying that he will be wearing a face-covering himself.

After a couple of weeks of media debate, a recent CNN article, pronounced, “Asia may have been right about coronavirus and face masks, and the rest of the world is coming around.”

Meanwhile health officials also seem to have come around. The CDC and White House expressed on Thursday that they may change the recommendation to wear masks shortly. While the WHO has reiterated its stance that people should not use masks, the consensus seems to be that this guidance may be to protect vital stores for hospitals.

In the United States there has been a boom in grandmothers making handmade masks – so much so that there is now a two week back order for elastic on Amazon. In addition major apparel companies like H&M (Sweden), New Balance (Massachusetts, USA) and others who have stepped up to begin making masks.

We see all of this as very positive for the West. But we expect it has had little effect on usage in Japan. Instead we think increasing supply, more people getting and holding on to their masks, more positive leadership from the government, and more concern by the citizenry has caused the increase.

Women Are Playing It Slightly Safer Than Men

It appears that women are playing it slightly safer than men. Our data showed that on March 13th, sixty-eight percent of women were wearing masks, compared to only sixty percent of men. In our April 2nd data, we found that ninety percent of women were wearing masks and eighty-two percent of men.

[Image #2] Percentage of Women and Men Wearing Masks on Mar 13, and on Apr 2.

Methodology

For all surveys they were conducted by assessing the number of commuters of each gender passing through a central Tokyo train station over a 90 minute period. For both the March and April surveys the weather conditions were remarkably similar, reflecting an unseasonably warm winter, so this is not seen as a significant factor.

Conclusions

In our previous research we reviewed several scientific studies that showed masks having a positive impact on the minimization of spread of infectious diseases. We are heartened to see the change in attitude in many western countries as they become supportive of masks as a tool that regular people can employ in helping to fight this pandemic. We are also happy to see Japan increasing its usage again, regardless of the reason.

Our team has been impressed with how fast opinions have changed in the west and how quickly people have produced novel solutions such as the entrepreneurial grandmas with their sewing machines. We are also impressed that so many companies are stepping up to offer their resources in creative ways to help beat this virus.

As we recommended in our internal article three weeks ago, we would like to see a more sustainable solution in fashionable, washable masks produced in Japan. If each person had three or four of these ready to go in their sock drawer, we could avoid future shortages of the “throw away” type masks.

On that note, the Prime Minister proposed distributing cloth masks to the general populace a few hours after we wrote the draft of this article. While some have argued that he needs to take more drastic steps to control the disaster, we think it is a step in the right direction.

Please send comments to: info@azabuinsights.com

About Azabu Insights

Azabu Insights is a boutique strategic consulting company based in Azabu Juban, Tokyo, Japan. Our teams work collaboratively with clients to build strategies that lead to positive change. Our multilingual team members have top tier academic backgrounds and deep industry experience that we leverage to provide first class, fully engaged, strategic consulting. Core specializations include life sciences, finance, electronics, automotives, aerospace and other industries. For more information contact: info@azabuinsights.com.

Avance Clinical on Top Reasons APAC Biotech Clients Choose Australia for Clinical Trials

Adelaide, AUS – (ACN Newswire) – Leading Australian CRO Avance Clinical today detailed the top reasons its APAC biotechs selected Australia for their early phase clinical trials, based on client onboarding feedback. Avance is a specialist Australian CRO with more than 20-years of early phase clinical trials expertise.

Avance Clinical said a primary reason that APAC biotechs chose Australia was the attractive Australian Government financial rebate of more than 40% on clinical trial spend. Avance Clinical CEO Yvonne Lungershausen said this makes good financial sense for biotechs in early clinical phases.

Another key factor is that, during the current COVID-19 pandemic, sites can pivot to patient video visits or telemedicine, which this week got a Government funding boost as part of a AUD$1.1 billion COVID-19 package.

Watch Avance Clinical COVID-19 capabilities video here: https://www.avancecro.com/

Ms Lungershausen said:

“This additional funding into an already high-tech medical environment means sites are rapidly able to incorporate telehealth visits to overcome challenges faced by patients not wanting to visit clinics during the pandemic.”

“Australia’s reputation for FDA compliant scientific and research excellence, its advanced healthcare, and the opportunity to access patients in a less clinical trial competitive environment further reinforces its advantage as a destination for clinical trials.”

“Avance is the CRO of choice for clinical trials – as well as those targeting COVID-19.”

The top reasons for selecting Australia are:

1. The Government R&D grant means more than 40% rebate on clinical trial spend

2. Telehealth pivot during COVID-19 pandemic – speed and continuity

3. Site Initiation Visit (SIV) and Study Start achieved in 5 – 6 weeks

4. No IND required for clinical trials

5. Full GMP material is not mandated for Phase I clinical trials

6. Established clinical trial environment with world-class Investigators and sites

7. Established healthy subject databases and specialised patient populations

8. Five independent Phase 1 facilities across Australia including hospital-based units for critical care

9. Major hospitals with world class infrastructures and dedicated Clinical Trial Units with a long track-record in FDA compliant research

10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies year-round by taking advantage of Australia’s counter-flu and allergy seasons

For more information about the benefits of running your next study in Australia contact us: https://www.avancecro.com/contact-us/

About Avance Clinical

Avance Clinical has more than 20-years of experience and is now one of Australia’s leading Contract Research Organisations. Avance Clinical facilitates quality drug development by aligning people, skills, and expertise in the pursuit of drug development for a healthier world.

Avance Clinical is committed to providing high-quality clinical research services with its highly experienced team. The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field.

Avance Clinical offers high quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialised patient groups. Other benefits include:

– Access to independent Phase 1 facilities across Australia including hospital-based units for critical care

– Dedicated Investigators committed to clinical research

– Major hospitals with world class infrastructures and dedicated Clinical Trial Units

– Expedited clinical trial start-up timeframes

Media Contact:

media@avancecro.com

Chris Thompson

Agilex Biolabs Taps Biopharma Leader Dr Caroline Popper for Board Chair as part of APAC Bioanalytical Services Growth

Adelaide, AUS – (ACN Newswire) – Award-winning Australian bioanalytical laboratory Agilex Biolabs announced today it has appointed US-based Dr Caroline Popper, MBBS, MPH as Board Chair as part of its APAC clinical trials bioanalytics growth plans.

More than 38% of Agilex Biolabs’ biotech clients already come from the APAC region – primarily from China and South Korea. APAC clients are particularly attracted by Agilex’ FDA-inspected status, and the more than 40% rebate on clinical trial spend that applies in Australia.

Agilex Biolabs specializes in bioanalysis of small molecules and biologics for PK, immunogenicity, biomarkers and immunological pharmacodynamics assessments, and the only FDA-inspected lab of its type in the region, is located in Adelaide, South Australia in a science and biotech specialist hub.

Dr Popper was first appointed to the Agilex Biolabs Board in July 2019.

Agilex Biolabs CEO Jason Valentine said:

“We are extremely pleased Dr Popper accepted the Board Chair role and we look forward to an exciting phase of growth under her guidance.”

“Dr Caroline Popper is a medical doctor, pathologist, health economist, medical consultant and experienced company director, with over 20 years of hands on experience in the healthcare, medical devices and drug discovery fields.

She has managed a wide range of diagnostics, device and drug discovery businesses in both Fortune 500 and start-up settings, at amongst others, Becton Dickinson, bioMerieux, and MDS.”

Dr Popper said:

“My clinical experience enables me to help interpret relevant market forces, develop strategies and create partnerships that thrive in the global and fast changing and challenging health care landscape.”

“Agilex Biolabs is a stand-out leader in the pharma services space and I look forward to taking on this significant role and being part of the next phase of growth for the company, leveraging its position in the important APAC region.”

“The Aglilex Biolabs team of scientists and specialist PhDs is quite exceptional making it well positioned to rapidly deliver bioanalytics for biopharma clients running clinical trials in Australia, Asia and the US, and the EU.”

The company specialises in bioanalysis of small molecules and biologics for PK, immunogenicity, biomarkers and immunological pharmacodynamics assessments utilising LC-MS/MS, immunoassay (Mesoscale, Gurolab, Luminex) and flow cytometry (BD FACSymphony A3, 20 colour cell analyser).

Agilex also offers pharmacodynamics services that include immunobiology services using the latest state-of-the-art technology to support immunology, cell biology and mode of action assays, including:

– Immunophenotyping

– Receptor occupancy

– Cytokine release assays (whole blood or PBMC stimulation assays) and cytokine/biomarker profiling

– PBMC assays and cellular mechanism of action assays (eg: ADCC)

CEO Jason Valentine said:

“Our FDA-inspected facilities have more than 65 dedicated laboratory staff, and annually support more than 80 clinical trials. This year we will analyse more than 60,000 samples for pharma/biotechs from US, Europe and APAC.”

“By combining specialised expertise, technological innovation and a 20-year track record, we have supported hundreds of preclinical and clinical trials around the world.”

“Our world-class bioanalytical facilities have OECD GLP Recognition with NATA (Australian Government OECD GLP Compliance monitoring authority) and ISO 17025 Accreditation for global recognition.”

Learn more about Agilex Biolabs in this Video: https://youtu.be/3lyodiqqM_k

About Agilex Biolabs

Agilex Biolabs began as a group of academic scientists providing clinical trial and bioanalytical services to the local Australian pharmaceutical industry in the 1980’s, and has now grown into a global business for early phase clinical trials. In our 20 years of performing regulated bioanalysis of small and large molecules, we have accelerated hundreds of preclinical and clinical trials around the world. Today, our clients include many of the leading pharmaceutical and biotechnology companies in Asia, Europe and the USA. Call +61 8 83028777 or +1 800 247 1909 or visit https://www.agilexbiolabs.com/.

Agilex Biolabs is built upon four core values that drive our performance:

– Scientific excellence and technological innovation

– Customer focus

– Data integrity and quality assurance

– Timeliness/speed

See us featured in Endpoints https://tinyurl.com/uqmkzcu

Media Contact:

Team@DMGPR.Com

David James

AU: +61 2 8218 2144

USA: +1 415 951 3228

Asia: +65 3159 3427

Contentos Partners with Decentralized Video Protocol Theta Network

NEW YORK, NY, Apr 3, 2020 – (ACN Newswire) – Contentos has partnered with the decentralized video delivery protocol Theta Network, which will be integrated with the COS.tv video platform to improve user experience and reduce the bandwidth cost of video content delivery.

COS.TV platform has achieved huge growth in 2019. According to Alexa ranking, in January 2020, the traffic of COS.TV has surpassed Steemit.com. However, the issue coming is the rapid rise in content delivery costs. By adding Theta Network to Contentos’ video infrastructure, we can reduce these costs by 50% or more, thereby enabling COS.TV to achieve more stable and sustainable growth, and adding a new way to increase user engagement through token rewards.

Theta Network, built by Theta Labs, is the leading decentralized video protocol based on blockchain technology. Theta Network uses token rewards to incentivize viewers to relay video using their excess bandwidth, providing users high-definition video content and reducing video distribution costs.

Earlier, Maekyung Media and CJ Hello, the two largest media companies in South Korea, have also agreed on a partnership with Theta Labs, which will use Theta’s decentralized video delivery.

Contentos co-founder and CEO Mick said: “We are very happy to work with Theta, which will help reduce our video content delivery costs and increase market share. The partnership also marks the development of blockchain technology adoption in video content.”

“We’re excited to bring COS.tv on to the Theta Network, and add to the growing number of platforms seeing real benefits from using Theta for video distribution” said Mitch Liu, CEO of Theta Labs. “As COS.tv continues to grow rapidly, Theta integration will help attract even more new users while keeping CDN costs low.”

About Contentos

Contentos (COS) is a decentralized global content ecosystem, which is invested jointly by Matrix Partners China, IDG, Gobi, and supported by Ontology, DHVC, Node Capital, Binance Lab, LD Capital, etc. Contentos aims to build the public chain platform that brings values back to content creators and users.

Contentos has reached a strategic partnership with the photo-editing tool PhotoGrid, the well-known live broadcast platform LiveMe, and the short-video platform Cheez. These three products have brought Contentos millions of global content creators and 60 million monthly users. In addition, Cheetah Mobile’s CleanMaster and related game products are also directly involved in the Contentos ecosystem. [www.contentos.io]

About Theta Network

Theta Network (Theta) aims to develop a more efficient way to distribute any type of content and data worldwide through an incentivized peer-to-peer network. The Theta blockchain uses its tokens to encourage individual users to share excess computing power and bandwidth resources as a relay node for video streams.
This mechanism can improve the quality of video streams and solve the “last mile” transmission problem, which is the main bottleneck of traditional information transmission channels, especially for 4K, 8K video and next-generation VR video. With sufficient network density, most users can pull video streams from peer Theta nodes, and video platforms can significantly reduce their costs of content delivery.

Theta Network introduces a token reward mechanism to help video platforms to attract users, increase revenue, and provide a more engaging viewing experience.

Contentos
Ava Wen
ava@contentos.io
+8869206868761

Cisco & Google Lead the Way in Ensuring Broad Coverage from Aetna and UnitedHealthcare for Young Pregnant Mothers

Founded by mothers for mothers, Stand Up! For Accurate Prenatal Answers (Stand Up! 4APA) is on a mission to ensure that all women in the U.S. have access to accurate and non-invasive prenatal genetic screening tests concerning fetal health.

Stand Up! For Accurate Prenatal Answers is pleased to see evidence of leading tech companies such as Cisco and Google affirming the right of women’s rights during pregnancy and pushing back on leading insurance companies who have generally restricted access to only pregnant women over the age of 35.

Nearly four million women in the United States, particularly women under 35, are being denied access to the benefits of reliable, accurate, and non-invasive prenatal screening tests, because of lack of insurance coverage, low income, and age-related discrimination. The result of this discrimination is:

– Too many false negatives: Up to 22% of Down syndrome cases are missed
– Too many false positives: Creating unnecessary anxiety for the mothers during pregnancy, expensive specialist referrals and invasive procedures that can result in the loss of the child

“Pregnancy is the most precious time in any woman’s life. Carrying another life within you for those treasured nine months is a blessing and a miracle. Stand Up! 4APA was created to provide a voice for young mothers who have gone through traumatic experiences because multi-billion dollar insurance companies like Aetna and UnitedHealthcare do not cover more accurate testing,” explains Cori Simmons, President, Stand Up! For Accurate Prenatal Answers. “While steps taken by Cisco and Google are encouraging, we implore women in other Silicon Valley companies take note and demand accurate prenatal answers”.

Company: StandUp4APA
Contact: Cori Simmons
Email: info@standup4apa.org
Phone:+1 616 727 0164
Website: Standup4apa.org

Suprema Marks 20th Anniversary with a New Emblem

SEOUL, KOREA – (ACN Newswire) – Suprema, a leading global provider of security and biometrics, is celebrating its 20th anniversary this year with an anniversary emblem, to commemorate the innovation and technical excellence of its partners and employees and the unique quality which represents the company, as it prepares for the next step – and the next 20 years.

Suprema was founded in 2000, and has since built a worldwide sales network spanning 140 countries, with a global population using Suprema technology now surpassing one billion. Its extensive portfolio includes access control, time & attendance, mobile access and fingerprint scanners.

Based on its innovative products and technologies, Suprema has recorded a phenomenal mean annual growth rate (CAGR) of 20%. At present, the company has more than 40% of its employees engaged in research and development, and it reinvests more than 16% of sales in R&D each year.

The anniversary emblem consists of two colors. ‘Infinite Burgundy’, the company’s brand color, symbolizes the infinite possibility in Suprema’s unique solution and technical skill. ‘Superior Purple’ is added to represent the uniqueness and excellence of the company that retains trust from 20 years of history and technological initiative.

“We would like to give special thanks to all our partners and employees who have made this possible,” founder and chairman of Suprema, James Lee, said. “Everyone at Suprema is ready to lead through our next 20 years.”

Suprema has grown into a corporate group, with subsidiaries and affiliates based on its exclusive world best technologies. Suprema HQ, the holding company, earned a place on KOSDAQ in 2008, followed by Suprema Inc. listing in 2016, and Suprema ID, an affiliate, listing last year. Suprema now plans to broaden its own position with a foothold in the global market. To learn more, please visit www.supremainc.com.

Press Contact:

Tae Woo Kim

Head of Marketing, Suprema Inc.

Email: twkim@suprema.co.kr

Zhonghua Gas Holdings Limited Announces 2019 Annual Results

HONG KONG – (ACN Newswire) – Zhonghua Gas Holdings Limited (the “Company”; Stock Code: 8246.HK) together with its subsidiaries (collectively as the “Group”) today announces its 2019 annual results. For the year ended 31 December 2019 (“the Current Year”), the Group recorded a 7.3% year-on-year increase in total revenue from continuing operations, from HKD366.7 million in the Previous Year to HKD384.9 million. The New Energy Business contributed over 99.9% to the Group’s total revenue. Profit and total comprehensive income attributable to owners of the Company decreased by 46.7%, from HKD94.6 million for the Previous Year to HKD49.4 million for the Current Year. Basic and diluted earnings per share for the Current Year was HKD1.5 cents and HKD1.3 cents respectively, as compared to HKD2.7 cents and HKD2.6 cents in the Previous Year. The Board did not recommend the payment of any dividend for the Current Year (Previous Year: HKD0.5 cent per ordinary share).

The main reasons for the drop in the gross profit ratio and net profit were that the liquefied natural gas (“LNG”) supplies had a lower gross profit margin and an expected credit losses provision was made for the trade receivables at RMB9.4 million (Previous Year: Nil). Moreover, the government subsidy was also reduced by RMB7.3 million for the Current Year.

During the Current Year, the Group focused on the expansion of the New Energy Business in terms of strengthening LNG supply during the heat supply period and enhanced its sales platforms and capabilities. The Group continued to obtain and complete a number of construction related and consultancy contracts. The subsidiary that operated LNG supply and related businesses brought stable income to the Group. The rental and management fees from LNG storage tanks and trading of new energy related industrial products were also other income sources for the Group.

The Group has been seeking new partnership in different regions, aiming to adopt a win-win strategy through co-exploring the LNG markets and securing stable LNG supplies with an extended and strong supply chain. At the end of last year, the Group successfully cooperated with Shanghai Jiulian Group, a wholly-owned subsidiary of the Shanghai Shenergy Group. Both parties agreed to form a Joint Venture to secure the supply of LNG resources and develop the business into the high potential market in the Yangtze River Delta region. Meanwhile, the Group continued to maintain strong business relationships with Tractebel Engineering S.A. from France and Tianjin Jinre Heat-Supply Group Co. Ltd.

Looking ahead, the Group will adopt a prudent business approach in near term to cope with the impact of COVID-19. The Group will actively identify suitable opportunities to develop any existing and new construction related and consultancy business. It will also cautiously execute strategic plans to enlarge its business scopes and take steps to gradually grow the scale of the LNG supply business, forge comprehensive partnership in the new energy sector as well as search for the PRC and international LNG suppliers to enrich its product portfolio. The Group’s determination to become a leading diversified and integrated new energy service provider in the PRC remains unchanged. It will concentrate on extending its New Energy business coverage to other major cities in the PRC and be committed to broadening its income streams to achieve sustainable profitability and assuring the supply of LNG resources.

About Zhonghua Gas Holdings Limited

Zhonghua Gas Holdings Limited is principally engaged in provision of diverse integrated new energy services including technological development, construction and consultancy services in relation to heat supply and coal-to-natural gas conversion, supply of liquefied natural gas, coupled with trading of new energy related industrial products. The Group is also engaged in the property investment business.

US Lighting Group Announces Mike Videmsek Joins Intellitronix Corporation as Director of Operations

EASTLAKE, OH / ACCESSWIRE – (ACN Newswire) – US Lighting Group, Inc. (OTCPINK:USLG), a leading manufacturer of electronics and high-tech robotics, announces its wholly-owned subsidiary, Intellitronix Corporation, appointed Mike Videmsek as Director of Operations.

“We are extremely happy to have Mike join Intellitronix during this critical juncture in our corporate growth as we are entering into new business ventures and high-tech electronics product development. Mike has a wealth of knowledge and experience in engineering and manufacturing operations having worked as Managing Director at Arconic, formerly, Alcoa,” said Paul Spivak, CEO of the US Lighting Group. “Mike will be responsible for the entire Intellitronix manufacturing operations including inventory, staffing, and budgets along with formulating an overall operations strategy with the objective of growing profits.”

Mike Videmsek has achieved career successes in high-tech industries, including commercial vehicle, automotive and aerospace. He is skilled in business planning and strategy, operations and production management, lean management, continuous improvement, multi-plant leadership, and workplace safety. Mike holds a Bachelor of Engineering (BEng) from Cleveland State University and a Master of Business Administration (MBA) from Baldwin-Wallace College.

Intellitronix is a leading electronics manufacturer who combines innovative ideas, expertise and technology to create cutting-edge solutions. Our state-of-the-art technology makes us one of the foremost designers and manufacturers of electronics. By only using the best and most advanced display and engineering techniques, we achieve the highest level of quality and performance for our products surpassing other companies in the marketplace.

About U.S. Lighting Group, Inc. and Intellitronix Corporation

US Lighting Group (OTCPINK:USLG) and its wholly-owned subsidiary, Intellitronix Corporation, are leading manufacturers of electronics, supplying growth sectors such as high-tech robotics utilizing our own in-house proprietary artificial intelligence, LED lighting, custom-designed LED products, microprocessor-controlled LED instrumentation, custom private labeled electronics, automotive, RV, and marine electronics. The company has manufacturing and R&D facilities in Cleveland, Ohio with an international sales distribution network. www.uslightinggroup.com

Forward-Looking Statements

Statements included in this press release, other than statements of historical fact, are forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are typically, but not always, identified by the words: believe, expect, anticipate, intend, estimate, and similar expressions or which by their nature refer to future events. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Actual results may differ materially from those indicated by these statements.

CONTACT:

US Lighting Group

34099 Melinz Pkway, Unit E

Eastlake, OH 44095 USA

T: +1 216.896.7000 ext. 207

shareholder-relations@uslightinggroup.com

SOURCE: US Lighting Group, Inc.